



August 13, 2007

Dear Fellow Shareholders of Nutra Pharma:

During the past several months, our Company has experienced strong growth in our drug discovery division, ReceptoPharm, as well as our medical devices division, Designer Diagnostics.

Towards the end of the 1st quarter, ReceptoPharm began its Phase IIb human clinical trial for the treatment of Adrenomyeloneuropathy (AMN). This was an important step for the Company, as it not only began one of our more significant trials, but it also laid the foundation for continued advancement into other studies for the treatment of neurological disorders, such as Multiple Sclerosis (MS). As of two weeks ago, the AMN trial achieved 100% successful enrollment.

In addition to making advancements in treatments for neurological disorders, we also announced a development in our treatments for the antiviral market. We discovered that our lead drug candidate, RPI-MN, activates the primary immune mechanisms. This discovery allows us to better understand the broad antiviral activity seen in past RPI-MN studies. In the future, we believe that RPI-MN could be used to substitute for the flu shot during the winter season. To follow up with this, we are planning to conduct two Phase II antiviral trials in South America.

Recently, ReceptoPharm successfully completed discussions with the Chinese biotechnology company, Nanogene Biotech, to create a joint venture in China as a platform to develop antiviral drugs for the Chinese market. This market is estimated to be approximately 10 times the size of the antiviral market in the United States, which would represent a potential market value of \$228 billion. This is an incredible opportunity for our Company, which we plan to continue pursuing.

In March, ReceptoPharm published a paper entitled “Alpha-Cobratoxin as a possible therapy for Multiple Sclerosis; a review of the literature leading to its development for this application” in the *Critical Reviews in Immunology* special conference issue. This article explains the significance of ReceptoPharm’s research for its treatment of Multiple Sclerosis using modified cobra venom.

Our medical devices division, Designer Diagnostics, has also seen important progress with the development of our Nontuberculous Mycobacterium (NTM) and Tuberculosis (TB) test kits. The recent in-vitro analysis of our TB test kit showed that our technology can achieve accurate results within 10 days rather than the currently available technology, which can take up to 8-10 weeks for results.



To bring the test kits to market, Designer Diagnostics has selected National Jewish Medical and Research Center in Denver, Colorado, to conduct 3rd party validation of our technology. We are currently working with the team of leading researchers and scientists at National Jewish to develop a protocol for the impending clinical trial, which we expect to begin within the 3rd quarter of 2007. This trial will be the final step required before gaining regulatory approval in the United States and abroad.

If you haven't already taken a moment to sign up for our e-mail alerts, be sure to do so by visiting www.NutraPharma.com. Signing up will ensure that you receive the latest news and announcements when they become available.

As part of our ongoing shareholder communications, we have included a brief question and answer section in this document. Our goal is to provide you with valuable information about the Company. In doing so, we have taken the most popular shareholder questions and have created responses for your review. As always, if you have any additional questions or would like more information, please contact our investor relations hotline at (877) 895-5647.

Sincerely yours,

A handwritten signature in blue ink, appearing to read 'Rik J. Deitsch', with a stylized flourish at the end.

Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation
Ticker Symbol: OTC: NPHC



Questions and Answers

How is the Company being capitalized?

I am just as excited today about the potential of Nutra Pharma as I was when I first took the reigns as Chairman of the Company. For this reason, I have provided much of the operating capital needed for the past 18 months. Last year alone, I funded over \$800,000 out of my own pocket. Right now, my number one priority is to help the Company become financially self-sufficient, which I believe can be accomplished through the sale of Designer Diagnostics' test kits.

Has the Company established a timeline for its drug development?

Yes, although research and development can many times take longer than originally expected. I have included a timeline below that outlines the anticipated timing of our current and future clinical trials.

Time	Drug Development		
1Q 2007		AMN Phase IIb	
2Q 2007			
3Q 2007	HIV Phase II		MS Phase II
4Q 2007			
1Q 2008	HIV Phase III (License)	AMN Phase III (License)	
2Q 2008			MS Phase III (License)
3Q 2008			
4Q 2008		Market AMN	
1Q 2009	Market HIV >\$10 Billion		
2Q 2009			Market MS >\$15 Billion

What is the status of the Designer Diagnostics test kits?

Designer Diagnostics and National Jewish Medical and Research Center are currently developing the protocol to conduct a clinical trial of the test kits. Once this trial is complete, Designer Diagnostics must then gain FDA regulatory approval to sell the kits in the United States.

This letter contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Nutra Pharma questions and answers should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.